Casi Pharmaceuticals Inc Expected To Post A Loss Of 6 Cents A Share: Earnings Preview

CASI Pharmaceuticals

25/03/2022 14:08

* CASI Pharmaceuticals Inc  CASI.OQ   CASI.O  is expected
to show
a rise in quarterly revenue when it reports  results on March
28. 
    * The Rockville Maryland-based  company is expected to
report  a
88.0% increase in revenue to $9.067 million from $4.82 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for CASI
Pharmaceuticals Inc
is for a loss of 6 cents per share. For the same quarter last
year, the company reported a loss of 12 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is $4​, above​ its last closing price
of $0.83. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.06       -0.05      -0.07     Missed  -27.3
 Jun. 30 2021  -0.08       -0.07      -0.05     Beat    31
 Mar. 31 2021  -0.06       -0.06      -0.11     Missed  -83.3​
 Dec. 31 2020              -0.07      -0.12     Missed  -71.4
 ​​Sep.        -0.06       -0.05      -0.14     Missed  -154.5
 30 2020                                                
 Jun. 30 2020  -0.08       -0.08      -0.07     Beat    12.5​
 Mar. 31 2020              -0.11      -0.09     Beat    18.2
 Dec. 31 2019              -0.11      -0.12     Missed  -9.1
 This summary was machine generated March 25 at 14:08 GMT.  All
figures in US dollars  unless otherwise stated